A Two-Part Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeat Doses of Inhaled ETD001 in People With Cystic Fibrosis
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Enterprise Therapeutics Ltd
- Target Recruit Count
- 40
- Registration Number
- NCT06478706
- Locations
- ๐ฎ๐น
Azienda Ospedaliera Universitaria Meyer, Florence, Italy
๐ฎ๐นIRCCS Istituto Giannina Gaslini, Genova, Italy
๐ฎ๐นFondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico, Milano, Italy
A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD001 in Healthy Subjects
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Enterprise Therapeutics Ltd
- Target Recruit Count
- 98
- Registration Number
- NCT04926701
- Locations
- ๐ฌ๐ง
Hammersmith Medicines Research, London, United Kingdom
A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Inhaled ETD002 in Healthy Subjects
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2021-05-21
- Lead Sponsor
- Enterprise Therapeutics Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT04488705
- Locations
- ๐ฌ๐ง
Hammersmith Medicines Research, London, United Kingdom
ยฉ Copyright 2024. All Rights Reserved by MedPath